EMERYVILLE - PhenomeX Inc. (Nasdaq: CELL), a functional cell biology company, announced the Opto Memory B Discovery Human workflow, further expanding diversity of antibodies customers can discover on the Beacon optofluidic platform.

The new workflow and reagents, to be commercially available by the end of the year, enable rapid, automated generation of antigen-specific, functional monoclonal antibodies from human memory B cells, building on prior workflows and reagents that used rabbit memory B cells and mouse plasma cells. Directly accessing the human repertoire with new workflow and reagents allows researchers to find more physiologically relevant and efficacious antibodies faster in a rapidly evolving biomedical field aimed at addressing infectious, autoimmune, and oncologic diseases.

Using the Opto Memory B Discovery Human workflow, PhenomeX estimates customers can: Prepare memory B cells from a wide variety of traditional enrichment strategies for screening in

(C) 2023 Electronic News Publishing, source ENP Newswire